Noninvasive stool DNA and FIT testing may significantly reduce the need for post-polypectomy colonoscopies, potentially decreasing procedures by 15% to 41%, according to a study from the Netherlands.
The Dutch MOCCAS study, published in Gastroenterology, on Monday highlights that annual FIT surveillance, particularly with FIT FOB-Gold at a threshold of 32 µg/g feces, may match colonoscopy in lowering colorectal cancer (CRC) incidence and mortality.
Lead author Beatriz Carvalho, noted, “With the worldwide implementation of FIT-based screening programs, more people enter surveillance after polypectomy, increasing pressure on colonoscopy capacity.”
While multitarget stool DNA tests excel in detecting advanced lesions like serrated polyps, they are more costly than colonoscopy surveillance. Conversely, FIT testing shows cost savings.
“Our hypothesis was confirmed that repeating molecular stool testing could yield detection rates comparable to colonoscopy,” Carvalho explained.
The study aligns with findings indicating FIT can effectively triage patients and extend surveillance intervals.
